The association between BsmI polymorphism and risk factors for atherosclerosis in patients with epilepsy taking valproate  by Phabphal, Kanitpong & Geater, Alan
Seizure 22 (2013) 692–697The association between BsmI polymorphism and risk factors for atherosclerosis
in patients with epilepsy taking valproate
Kanitpong Phabphal a,*, Alan Geater b
aNeurology Unit, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
b Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
A R T I C L E I N F O
Article history:
Received 18 January 2013
Received in revised form 30 April 2013






A B S T R A C T
Purpose: To evaluate the association between the BsmI polymorphism and vascular risk factors or
metabolic syndrome in patients with epilepsy treated with valproate.
Methods: We performed a cross-sectional study to determine glucose homeostasis, lipid proﬁle, and
evidence of metabolic syndrome, as well as the BsmI polymorphism in seizure free adults with epilepsy.
Results: We recruited 75 patients with epilepsy to the current study. The frequency of the BsmI
polymorphism was 22.7%. We found that patients with BsmI polymorphism had signiﬁcantly higher
total levels of triglycerides, total cholesterol, HDL-C and LDL-C. There were no differences in terms of
fasting blood glucose level and fasting insulin levels between patients with the BsmI polymorphism and
those with the wild type vitamin D receptor (VDR) gene. Insulin resistance was identiﬁed in 6 of 17
patients with the BsmI polymorphism, and 18 of 58 patients with the wild type VDR gene. We calculated
the homeostasis model assessment (HOMA) index and found no difference in HOMA levels between the
groups. Systolic blood pressure was higher in patients with the BsmI polymorphism. There was a higher
prevalence of metabolic syndrome in patients with the BsmI polymorphism than in patients with the
wild type gene. The prevalence of metabolic syndrome in BsmI polymorphism carriers was 64.7%
compared with 41.4% in patients with the wild type VDR gene.
Conclusion: Young patients with epilepsy taking valproate who carry the BsmI polymorphism are at an
increased risk of having vascular risk factors.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Epidemiological research has indicated that the prevalence and
death rate from arteriosclerosis related cardiovascular disease are
slightly elevated in adult epilepsy patients taking antiepileptic
drugs (AEDs).1 According to one pathogenetic hypothesis valproate
may contribute to the risk of atherosclerosis: high levels of serum
uric acid in patients with valproate may be associated with the
development of atherosclerosis.2 An oxidative stress/antioxidant
dysequilibrium3 and elevated total plasma homocysteine have also
been found in patients who had received prolonged treatment with
valproate.4,5 Valproate may also contribute to atherosclerotic
vascular disease by inducing a metabolic syndrome.6 The
prevalence of metabolic syndrome in patients taking valproate
is higher than in the general population, especially if valproate is
taken for bipolar disorder7 or epilepsy.8 However, studies of the* Corresponding author. Tel.: +66 74451452; fax: +66 74429385.
E-mail addresses: pkanitpo@medicine.psu.ac.th, pkanitpo@gmail.com
(K. Phabphal).
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http://dx.doi.org/10.1016/j.seizure.2013.05.003effects of valproate in epileptic patients have mostly been of poor
design and have yielded conﬂicting results.8,9 The reasons why
valproate causes metabolic syndrome in some but not all patients
remain unclear and controversial. Genetic factors that inﬂuence
the several molecular pathways involved in energy homeostasis
may offer a possible explanation.
Among the fundamental biological effects of the active form of
vitamin D, i.e., 1,25(OH)(2)D(3), are the control of calcium and
bone metabolism and the regulation of the proliferation and
differentiation of many cell types. Vitamin D receptors (VDR) are
present in pancreatic beta-cells. 10 Vitamin D may therefore be
involved in glucose homeostasis by inﬂuencing the regulation of
insulin secretion.11 A previous study has proposed an inverse
relationship between vitamin D status and the risk of developing
diabetes, insulin resistance (IR), and metabolic syndrome.12 BsmI
polymorphisms are useful genetic markers of bone mineral density
(BMD) and the risk of osteoporosis, and have been described in
relation to obesity and type 2 diabetes mellitus.13 VDR is also
expressed in adipocytes, and vitamin D could be directly involved
in the regulation of adipocyte differentiation and metabolism as
well as have an impact on lipoprotein lipase expression.14vier Ltd. All rights reserved.
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relationship of BsmI polymorphism and lipid proﬁles.
The aim of this study was to discover whether there is an
association between BsmI polymorphisms and lipid abnormalities,
glucose homeostasis and metabolic syndrome in patients with
epilepsy taking valproate.
2. Methods
We performed a cross-sectional study to determine the
characterization of glucose homeostasis, lipid proﬁle, and meta-
bolic syndrome in adult epilepsy patients. We recruited our
patients from the outpatient clinics of Songklanagarind Hospital
from May 2011 to May 2012.
The inclusion criteria were: Thai nationals with epilepsy; aged
15–55 years; had received valproate monotherapy for at least 1
year; were seizure free for at least 1 year; had no chronic medical
illness other than epilepsy; were taking no medication except
valproate; and had a stable body weight over the 6 months prior to
inclusion. All subjects performed regular aerobic exercise, at least
30 min three times a week, for at least 3 months before inclusion.
The exclusion criteria were: having signiﬁcant medical
disorders other than epilepsy known to affect lipid or glucose
homeostasis; having a signiﬁcant disability, such as mental
retardation, ataxia, paresis, or other motor disability, learning
disability, language disorder, hearing or visual disability, psychosis
or psychiatric disease; taking medications known to affect lipid or
glucose homeostasis, e.g., steroids, glucocorticoids, thiazides, lipid
lowering agents, except antiepileptic drugs; or having a family
history of diabetes.
All patients completed a questionnaire covering sex, age, age at
onset of epilepsy, duration of treatment, occupation and medica-
tion. Weight and height were also measured and the body mass
index (BMI) was calculated [body weight (kg)/height (m2)]. A BMI
in the range of 18.5–23.0 was considered normal, higher than 23.0
overweight, and lower than 18.5 underweight. Wrist circumfer-
ence was also measured.
Each patient’s epilepsy was classiﬁed using the new ILAE
Commission on Classiﬁcation and Terminology 2005–2009.15 The
diagnosis of epilepsy was based on clinical data obtained from
medical records electroencephalography (EEG) and neuroimaging
ﬁndings, and, for some speciﬁc syndromes, age at onset. Mode of
onset was classiﬁed as generalized if the patient had generalized
seizures and showed generalized epileptiform discharge on the
EEG. Focal onset seizures were classiﬁed if the subject had a history
of focal onset seizures, and either an EEG or a neuroimaging ﬁnding
which showed a focal abnormality or normal studies. EEGs and
neuroimaging were performed on all of the patients. The interictal
EEG was abnormal in 47% of patients and normal in 50%. The
abnormal EEGs included epileptiform discharge in 66% of patients,
generalized slowing of the background activity in 20%, and focal
slowing in 14%. The ictal EEG changes were captured in 3% of
participants. We classiﬁed the etiology as genetic, structural/
metabolic, or unknown. Subjects were classiﬁed as genetic if they
had a known genetic mutation for their epilepsy, or if they had an
epilepsy syndrome which is known to be closely linked to genetic
causes. The etiology was deﬁned as unknown in subjects with a
normal neurological examination, normal laboratory results
(including neuroimaging), and no family history of epilepsy. A
structural/metabolic etiology was deﬁned as epilepsy resulting
from certain structural abnormalities of the brain, or metabolic
conditions. All of the EEGs were interpreted by an EEG certiﬁed
epileptologist. The MRI ﬁndings were conﬁrmed by a neuroradiol-
ogist.
The metabolic syndrome was deﬁned as follows, at least three
of following criteria had to be met: (1) abdominal obesity, (2)hypertriglyceridemia (at least 150 mg/dl), low high-density
lipoprotein (HDL) cholesterol (<40 mg/dl in men and <50 mg/dl
in woman), (3) hypertension (at least 130/85 mmHg), and 4)
impaired glucose tolerance.16
2.1. Laboratory procedures
Laboratory determinations were performed in the morning
after a 10-h overnight fasting period. The serum glucose level was
determined by the Enzymatic Method of Hexokinase (Modular
P800; Roche Diagnostics: Tuttlingen Germany) and the serum
insulin level by Electrochemiluminescence immunoassay [ECLIA]
(Modular E170; Roche Diagnostics: Mannheim Germany). The
sensitivity of the assay was 0.200 mU/L, and the coefﬁcients of
variation were 1.38% and 0.87% for intra-assay, and 4.20% and
3.97% for interassay (intra-assay: n = 20, mean = 24.06 mU/L,
SD  0.33 and mean = 80.05 mU/L, SD  0.70; interassay: n = 20,
mean = 22.70 mU/L, SD  0.95 and mean = 79.26 mU/L, SD  3.15).
Serum cholesterol level was determined by the CHOD-PAP enzymatic
assay method (Modular P800; Roche Diagnostics: Tuttlingen
Germany), the triglyceride level was determined by the GPO-PAP
enzymatic assay method (Modular P800; Roche Diagnostics:
Tuttlingen Germany), the high-density lipoprotein-cholesterol level
(HDL-C) was determined using a precipitation procedure with
dextran sulfate and magnesium chloride, and the low-density
lipoprotein-cholesterol level (LDL-C) was calculated according
to the Friedewald formula. Using the fasting glucose and insulin
levels, we calculated the homeostasis model assessment (HOMA)
index for each patient. The equation was as
follows:HOMA  index ¼ fasting glucose ðmmol=LÞfasting insulin ðmIU=LÞ22:5
HOMA values have been shown to correlate well with values
obtained using the ‘‘gold standard’’ clamp technique.17 Using a
threshold of 1.73, the patients were classiﬁed as having insulin
resistance.18
2.2. Vitamin D receptor
Genomic DNA was isolated from leukocyte nucleids using QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany). Realtime PCRProbe (realtime
polymerase chain reaction probe) was performed in a strip tube with a
reaction volume of 20 ml, containing 2 ml of SsoFast Probe Supermix
‘‘BioRad’’ (Hercules, CA, U.S.A.) (ready to use reactionmix), 0.15 mM of
the sense, antisense and probe primers for VDR and 150 ng/ml of
genomic DNA. The sequences primer and probe for realtime used PCR
were VDR sense 50GAGCCCAGTTCACGCAAGAG30,VDR antisense
50GGGGGGATTCTGAGGAACTAGATA30,VDR 6-FAM-50ACAGGCCTGC
GCATTCCCAAT30-TAMRA for wild type and VDR HEX-50ACAGGC-
CTGCACATTCCCAAT30-TAMRA for mutation.19
Realtime PCR Probe ampliﬁcation to detect for VDR was
performed using CFX 96 Connect Realtime-PCR (Bio-Rad Labora-
tories) with an initial denaturation at 95.0 8C for 2 min, followed
by 35 cycles denaturation 95.0 8C for 10 s, annealing 60.0 8C for
30 s, 35 cycles, and ﬁnal extension at 95.0 8C for 10 s. Analysis
Software by CFX manager 2.1 (Life Science Research, Hercules,
CA, U.S.A.).
Realtime PCR HRM (realtime polymerase chain reaction high
resolution melting) was performed in a strip tube with a reaction
volumeof20 ml,containing2 mlofSsoFastEvagreenSupermix‘‘BioRad’’
(readytousereactionmix),0.15 mMoftheforwardandreverseprimers
and 100 ng/ml of genomic DNA. The sequences of forward and reverse
primers used were 50TAGGGGGGATTCTGAGGAACTA30and 50AGTT-
TTGTACCCTGCCCGC30.
Ampliﬁcation to detect VDR was performed using CFX 96
Connect Realtime-PCR (Bio-Rad Laboratories, Hercules, CA, U.S.A.)
with an initial denaturation at 95.0 8C for 3 min, followed by 40
cycles of denaturation 95.0 8C for 10 s, annealing 60.0 8C for
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95.0 8C, increment 0.2 C, 10 s. The HRM analysis employed the
Precision Melt Analysis software 1.1 (Life Science Research).
Aliquots (8 ml) of produced Realtime PCR HRM product were
digested with 5 U Bsm I restriction enzymes at 65 8C for 1 h (New
England BioLabs, Ipswich, MA, U.S.A.) and detected using 12%
polyacrylamide gel electrophoresis run at 120 V for 2 h 30 min.
Conﬁrmation was made using sequence ABI 3130 Genetic Analyzer
(3130 Collection Software, Life Technologies, Grand Island, NY, USA).
The Ethics Review Committee of the Faculty of Medicine, Prince
of Songkla University, approved the study and informed consent
was sought and obtained from all patients.
2.3. Statistical analysis
The characteristics of the study patients were described in
terms of mean and standard deviation for continuous variables,
and number and percentage for categorical variables. Comparisons
of continuous variables between the two subgroups of subjects
were performed using a two-tailed t-test and of categorical
variables using the chi-square test. The correlations between
fasting blood sugar, fasting insulin, total cholesterol, triglycerides,
LDL, HDL, systolic blood pressure, diastolic blood pressure, BMI and
duration of treatment with valproate were explored using the
Pearson product movement correlation coefﬁcient. P-values of
0.05 were considered statistically signiﬁcant. Statistical analyses
were performed using Stata version 7.0 (Stata Statistical Software:
Level 7.0 College Station, TX, USA).
3. Results
Seventy-ﬁve epilepsy patients took part in the study. Forty-
three patients had focal onset epilepsy and 32 patients had
generalized epilepsy. Of these, the cause of the seizure was
regarded as unknown in 36% and structural (remote central
nervous system infection and traumatic brain) in 64%. None of the
patients had a family history of epilepsy. A majority (85%) were
seizure free for more than 24 months.
Basic clinical characteristics, lipid proﬁle, fasting blood glucose
level, fasting insulin levels, HOMA, and VDR genotype are shown in
Table 1. In our study, the prevalence of BsmI polymorphism was
22.7%. Overall, the mean age SD was 32.8  12.3 (range: 15–55)
years; 35 were male and 40 female. The mean duration of treatment
with epileptic drugs  SD overall at the time of the study wasTable 1
Basic clinical characteristics, lipid proﬁle, fasting blood glucose, insulin levels, HOMA, 
Characteristics VDR genotype 
BsmI polymorphism (17) 
Mean  SD 95% CI 




Duration of treatment (years) 3.7  1.0 3.23–4.
Systolic blood pressure (mm Hg) 136  8 131–14
Diastolic blood pressure (mm Hg) 78  10 73–84
BMI (kg/m2) 23.2  3.5 21.4–25
Fasting blood glucose (mmol/L) 98.0  14.0 92.2–10
Fasting blood insulin (mIU/L) 6.7  1.3 3.5–7.
Total triglyceride (mg/dl) 161.9  25.9 148.6–17
Total cholesterol (mg/dl) 270.5  38.7 250.7–29
LDL cholesterol (mg/dl) 154.0  32.6 137.2–17
HDL cholesterol (mg/dl) 62.3  7.6 58.4–66
HOMA 1.59  0.26 1.72–1.
BMI: body mass index; LDL: low-density lipoprotein cholesterol; HDL: high-density 
receptor, 95%CI: 95% conﬁdence interval.4.0  1.0 (range: 2–7) years. The 17 patients with a BsmI polymor-
phism (homozygotes, heterozygotes) had a mean age  SD of
31.5  12.9 (range: 17–55 years); 9 were male and 8 female, and
their mean duration of treatment  SD was 3.7  1.0 (range: 2–7)
years. The 58 patients who had the wild-type VDR gene had a mean
age  SD of 33.2  12.2 (range: 16–55) years; 26 were male and 32
female, and their mean duration of treatment  SD was 4.1  1.1
years (range: 2–7 years). There was no signiﬁcant difference in age,
sex or duration of treatment between epilepsy patients with BsmI
polymorphism and epilepsy patients with the wild-type VDR gene
(p = 0.61, 0.35 and 0.25 respectively). Surprisingly, no correlations
between duration of valproate treatment and total triglycerides, total
cholesterol, HDL-C and LDL-C, fasting blood glucose and fasting
insulin level, or HOMA as well as metabolic syndrome, were detected
in either group.
We further compared the individual components of the
metabolic syndrome parameters between groups. In the lipid
proﬁle, we found that epilepsy patients with BsmI polymorphism
had signiﬁcantly higher total triglycerides, total cholesterol, HDL-C
and LDL-C than those with the wild-type VDR gene (161.9  25.9
vs. 144.8  23.6, p = 0.01; 270.5  38.7 vs. 241.9  36.6, p < 0.01;
62.3  7.6 vs. 57.1  8.1, p = 0.02; 154.0  32.5 vs. 133.5  27.9,
p = 0.01, respectively). For glucose homeostasis: fasting blood glucose
and fasting insulin level showed no statistically signiﬁcant difference
between epilepsy patients with BsmI polymorphism and those with
the wild-type VDR gene (98.0  14.0 vs. 97.4  10.6, p = 0.85,
6.7  1.3 vs. 7.06  1.46, p = 0.37 respectively). Again, we calculated
the HOMA and found that HOMA showed no statistically signiﬁcant
difference between epilepsy patients with BsmI polymorphism and
those with the wild-type VDR gene (p = 0.11). Insulin resistance was
identiﬁed in 6 of 17 epilepsy patients with BsmI polymorphism, and
18 of 58 epilepsy patients with the wild-type VDR gene. However, no
patient satisﬁed the criteria of diabetes mellitus in our study. The
mean systolic blood pressure (SD) was higher in patients with BsmI
polymorphism (p = 0.02), although there was no statistically signiﬁ-
cant difference in diastolic blood pressure (p = 0.75). Other variables
are shown in Table 1. BMI of epilepsy patients with BsmI
polymorphism was higher than that of patients with the wild-type
VDR gene (23.2  3.5 vs. 21.1  3.2 p = 0.02). Ten of the 17 patients
with BsmI polymorphism (58.8%) had a high BMI (>23.0) compared
with only 13 of the 58 patients with the wild-type VDR gene (22.4%).
Metabolic syndrome was present in 11 of the 17 patients with BsmI
polymorphism (64.7%) compared with 24 of the 58 patients with the
wild-type VDR gene (41.4%). Table 2 shows the prevalence ofand VDR genotype.
p value
Wild type (58)
Mean  SD 95% CI
.1 33.2  12.2 30.0–36.4 0.61
26 0.35
32
3 4.1  1.1 3.8–4.3 0.25
0 129  9 127–132 0.02
 79  9 77–82 0.75
.1 21.1  3.2 20.2–21.9 0.02
1.3 97.4  10.6 89.4–93.5 0.85
8 7.06  1.46 2.1–22.3 0.37
5.2 144.8  23.6 138.6–151.1 0.01
0.4 241.9  36.6 232.3–251.6 <0.01
0.8 133.5  27.9 126.2–140.9 0.01
.2 57.1  8.1 55.0–59.3 0.02
97 1.69  0.15 1.62–1.75 0.11
lipoprotein cholesterol; HOMA: homeostasis model assessment; VDR: vitamin D
Table 2
Lipid proﬁle, fasting blood glucose, blood pressure, BMI and individual components of metabolic syndrome by sex in unfavorable VDR polymorphism.
Variable Male (9) Female (8) p-value
Mean  SD 95% CI Mean  SD 95% CI
Glucose homeostasis
Fasting blood sugar (mmol/L) 96.1  8.8 89.4–102.9 97.5  3.3 89.6–105.4 0.76
HOMA 1.88  0.14 1.77–1.99 1.81  0.32 1.54–2.07 0.57
Lipid proﬁle
Total cholesterol (mg/dL) 275.2  32.48 250.3–300.2 265.3  32.5 250.3300.19 0.61
Triglyceride (mg/dL) 155.7  27.1 134.9–176.5 168.9  24.3 148.6–189.2 0.31
LDL cholesterol (mg/dL) 160.6  24.4 141.8–179.4 146.5  40.5 112.7–180.4 0.39
HDL cholesterol (mg/dL) 63.3  8.1 57.1–69.6 61.1  7.4 54.9–67.3 0.56
Systolic blood pressure (mgHg) 133.6  7.9 127.5–139.6 137.6  9.1 130.1–145.4 0.32
Diastolic blood pressure (mmHg) 77.1  10.2 69.3–84.9 80  3.7 71.2–88.8 0.57
BMI (kg/m2) 22.6  5 18.7–26.4 21.1  5 16.9–25.3 0.57
BMI: body mass index; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; HOMA: homeostasis model assessment.
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patients with BsmI polymorphism; no statistical signiﬁcance
between male and female was evident.
4. Discussion
To our knowledge, this is the ﬁrst study of the possible role of
the BsmI polymorphism in relation to metabolic syndrome in
patients with epilepsy taking valproate. The results of this study
support the existence of a signiﬁcant positive association between
the presence of BsmI polymorphism and metabolic syndrome in
young adults with epilepsy taking valproate. Epilepsy patients who
had the BsmI polymorphism had higher total cholesterol, total
triglycerides, LDL-C, triglycerides, HDL-C and BMI than patients
with the wild-type VDR gene, but no signiﬁcant differences in
fasting blood sugar, fasting insulin level or insulin resistance. In
addition, the mean systolic blood pressure was higher in epilepsy
patients with the BsmI polymorphism.
Our study provides evidence that epilepsy patients with the BsmI
polymorphism are more likely to have metabolic syndrome than
epilepsy patients with the wild type. These results are in agreement
with other studies.20–22 Metabolic syndrome is described as a link
between insulin resistance, hypertension, dyslipidemia and type-2
diabetes. Metabolic syndrome is associated with an increased risk of
atherosclerotic cardiovascular disease in adults. Recently, conﬂicting
results regarding the association between metabolic syndrome and
valproate in epilepsy patients have been reported.4,5 The divergent
ﬁndings may be explained by confounding factors, especially
differences between the studies in terms of physical activity, weight
change and, most importantly, genetic susceptibility of the
participants. We conducted our study on epilepsy patients living
in a tropical Asian country who exercise regularly. We found a
prevalence of metabolic syndrome of 46.7% overall. The prevalence of
metabolic syndrome in epilepsy patients with the BsmI polymor-
phism was 64.7%, in non-polymorphism carriers it was only 41.4%.
In terms of metabolic syndrome components, our study found
that epilepsy patients with the BsmI polymorphism had signiﬁ-
cantly higher total cholesterol, total triglyceride, HDL-C, and LDL-C
levels than did patients with the wild type (p = <0.01, 0.01, 0.02,
0.01 respectively). Our ﬁndings also demonstrate a greater
prevalence of obesity in epilepsy patients with the BsmI
polymorphism. These characteristics may indicate that obesity
facilitates the development of metabolic syndrome in epilepsy
patients with BsmI polymorphism. However, recent studies have
demonstrated that metabolic syndrome is more common in obese
patients with epilepsy on valproate than in obese people in
general.23,24 Having said that, not all obese patients taking
valproate develop metabolic syndrome. These ﬁndings support
the concept that the development of metabolic syndrome amongobese patients treated with valproate is different from that among
the general obese population.
Previous reports have found a link between insulin resistance and
valproate.25,26 Some studies have demonstrated that obese patients
on VPA therapy have increased insulin levels with insulin
resistance.26,27 Most studies have been conducted in Western
countries, which differ in terms of food, culture and genetics from
Eastern countries. A study of an Asian population did not show any
statistically signiﬁcant difference in insulin resistance between
patients taking valproate and patients taking no antiepileptic drug.28
The factors that cause individual differences remain unclear. Both
environmental and genetic factors could contribute to such
differences. It is now clear that the vitamin D endocrine system
plays an important role in the mechanism regulation of insulin
release and the maintenance of glucose tolerance, and can inﬂuence
insulin sensitivity.26 The fundamental biological effects of the
actions of the active form of vitamin D, especially 1,25 hydro-
xyvitamin D are exerted on multiple organs. The vitamin D
endocrine system regulates cellular differentiation and replication
in many target tissues, including the pancreas and adipose tissue; it
also regulates blood pressure and volume homeostasis. Variations in
this endocrine system can lead to several common chronic diseases
and metabolic syndrome. Vitamin D and its analogs exert their
actions through the VDR, which is a member of the steroid hormone
receptor superfamily. Chromosome 12q12-q13 is the location of the
VDR-encoding gene; it comprises 11 exons which together with
accompanying introns creates about 75 kb of genomic DNA.29 BsmI
polymorphism occurs in the intron between exons VIII and IX in the
30 region of the hVDR. Previous studies have associated the VDR BsmI
polymorphism with Type 1 DM.30 Recently, associations of VDR
polymorphism with elevated postprandial insulin levels and type 2
DM have been reported.31 Ortlepp et al., analyzing the VDR gene and
fasting glucose in healthy young men with low physical activity,
found that the BsmI polymorphism is associated with altered fasting
blood glucose levels, but this effect was absent in gene carriers with
high physical activity.32 An association between BsmI polymor-
phism and insulin resistance was found in a non-diabetic Caucasian
population by Oh et al.33 They observed that persons with
homozygous BsmI polymorphism showed signiﬁcantly higher levels
of HOMA-IR compared with those with heterozygous BsmI
polymorphism and the wild type VDR gene, especially after
additional adjustment for calcium and vitamin D use. The
mechanism is still unclear. However, the possible mechanism of
the VDR gene transcription might inﬂuence fasting glucose levels by
two potentially additive effects of vitamin D in adipocytes and
pancreas cells.34 The effect of vitamin D in the role of insulin
secretion may be ﬁrstly, 1,25 hydroxyvitamin D directs insulin
secretion in the b cell through an increase in intracellular free
calcium concentration via a nonselective calcium channel.35
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growth by the up regulation of vitamin D receptors, suggesting VDR
variants might alter insulin secretion or insulin responses through
early b cell differentiation.36 In contrast, our study did not show any
statistically signiﬁcant difference in fasting blood glucose levels,
fasting insulin levels, or insulin resistance between epilepsy patients
with BsmI polymorphism and patients with the wild type VDR gene.
This ﬁnding is supported by other studies.37,38 These data are in
conﬂict, because the ﬁndings of an individual study may be affected
by confounding factors, such as physical activity, family history, and
differences in dietary intake. In our study, we excluded patients with
a family history of diabetes, and included only patients who
exercised regularly. Our study also demonstrated that the HOMA
index is related to metabolic syndrome rather than BMI. Our analysis
revealed no association between obesity and insulin resistance or
between obesity and fasting blood sugar.
Hypertension is one of the important components of metabolic
syndrome. Hypertension is associated with low blood levels of
ionized and untraﬁltrable calcium.39 Although hypocalcemia may
be a causal factor for the development of hypertension, a plausible
mechanism for the association of vitamin D deﬁciency/insufﬁciency
and hypertension is an activation of the renin-angiotensin system
(RAS). Inappropriate stimulation of the RAS has been associated with
hypertension. Today, there are limited data available to evaluate the
effect of VDR gene polymorphisms, especially the BsmI polymor-
phism, in the regulation of blood pressure in humans. Muray et al.’s
study demonstrates the inﬂuence of BsmI polymorphism of the VDR
gene on blood pressure in healthy men. In the wild type VDR gene,
blood pressure levels were clearly lower and, only in them, was
vitamin D positively correlated with blood pressure. No inﬂuence of
the BsmI polymorphism on blood pressure was observed in women.
These data reveal that the pathophysiology interaction between
vitamin D and sex hormones plays a role in the control of blood
pressure.40 Our study supports the evidence that BsmI polymor-
phism has a positive correlation with blood pressure. This effect was
found in both sexes.
There are several limitations to this study. First, it is cross-
sectional, which limits the investigation of causal relationships. The
second limitation of our study is the rather modest sample size. The
third limitation is the lack of dietary data; dietary intake was
estimated using the recall technique over a short period of time, thus
it may not be a good representation of usual or long-term dietary
intake. Together, all the methods used to assess self-reported daily
dietary intake have several limitations in terms of the accuracy.41
Finally, there was a lack of normal control subjects. In the futures, we
will conduct a study with a larger sample size, compare other
antiepileptic drugs, and use normal subjects as the control group.
In summary, the BsmI polymorphism in patients with epilepsy
on valproate was associated with a signiﬁcantly higher prevalence
of metabolic syndrome and obesity as well as higher levels of
serum level total triglycerides, total cholesterol, LDL-C, HDL-C and
systolic blood pressure. This knowledge when weighing up the
pros and cons of the use of valproate in individual patients with
epilepsy. Genetic markers that help identify individuals at high risk
for a particular metabolic effect, which is itself a vascular risk factor
for morbidity and mortality, may be useful in guiding treatment
decisions, especially in Asian countries.
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